相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment
Michael Cronquist Christensen et al.
CNS SPECTRUMS (2023)
Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability
Michael Adair et al.
JOURNAL OF AFFECTIVE DISORDERS (2023)
Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review
Javier De Diego-Adelino et al.
EXPERT OPINION ON DRUG SAFETY (2022)
The relationship between dose and serotonin transporter occupancy of antidepressants-a systematic review
Anders Sorensen et al.
MOLECULAR PSYCHIATRY (2022)
Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
Eugenia Papalexi et al.
BMC PSYCHIATRY (2022)
Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan
Takeshi Inoue et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2021)
Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset
Nadia Iovieno et al.
JOURNAL OF CLINICAL PSYCHIATRY (2021)
Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
Roger S. McIntyre et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2021)
Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder
Takeshi Inoue et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2020)
Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study
Vera De Carlo et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2020)
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Xenia Gonda et al.
EXPERT OPINION ON DRUG DISCOVERY (2019)
Antidepressants and Sexual Dysfunctions: a Translational Perspective
Jocelien D. A. Olivier et al.
CURRENT SEXUAL HEALTH REPORTS (2019)
Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient
Oloruntoba J. Oluboka et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)
Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder
Akira Nishimura et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2018)
The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: An in vitro study in rat hippocampus slices
Elena Dale et al.
BRAIN RESEARCH (2018)
Efficacy of vortioxetine on the physical symptoms of major depressive disorder
Michael Cronquist Christensen et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Modeling and Mutational Analysis of the Binding Mode for the Multimodal Antidepressant Drug Vortioxetine to the Human 5-HT3A Receptor
Lucy Kate Ladefoged et al.
MOLECULAR PHARMACOLOGY (2018)
Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines
Michael Bauer et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2017)
Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systematic review and meta-analysis
Stefanie Wagner et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2017)
A study of time- and sex-dependent effects of vortioxetine on rat sexual behavior: Possible roles of direct receptor modulation
Yan Li et al.
NEUROPHARMACOLOGY (2017)
The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
Ioana Florea et al.
BRAIN AND BEHAVIOR (2017)
New Empirical Definition of Major Depressive Episode Recovery and Its Positive Impact on Future Course of Illness
Lewis L. Judd et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments
Sidney H. Kennedy et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2016)
A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults
Michael E. Thase et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms
David S. Baldwin et al.
JOURNAL OF AFFECTIVE DISORDERS (2016)
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
David S. Baldwin et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder
Paula L. Jacobsen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines
Anthony Cleare et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data
Connie Sanchez et al.
PHARMACOLOGY & THERAPEUTICS (2015)
A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
Atul R. Mahableshwarkar et al.
PSYCHOPHARMACOLOGY (2015)
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
Jean-Philippe Boulenger et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults
Roger S. McIntyre et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D)
Waguih William IsHak et al.
JOURNAL OF AFFECTIVE DISORDERS (2013)
The effect of prolonged duration of untreated depression on antidepressant treatment outcome
Jens Drachmann Bukh et al.
JOURNAL OF AFFECTIVE DISORDERS (2013)
Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects
Johan Areberg et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2012)
Onset, time course and trajectories of Improvement with antidepressants
Raymond W. Lam
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Early Response and Remission as Predictors of a Good Outcome of a Major Depressive Episode at 12-Month Follow-Up: A Prospective, Longitudinal, Observational Study
Antonio Ciudad et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
A. Mork et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
Benny Bang-Andersen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder
Akiko Okuda et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2010)
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Stuart A. Montgomery et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2009)
Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression
Verena Henkel et al.
JOURNAL OF AFFECTIVE DISORDERS (2009)
Early Improvement in the First 2 Weeks as a Predictor of Treatment Outcome in Patients With Major Depressive Disorder: A Meta-Analysis Including 6562 Patients
Armin Szegedi et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale
Kathy Harnett Sheehan et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients
Hans H. Stassen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
分享论文
